Delivery Order SPE2DR25D1109-SPE2DR26FFF3M
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $22,624.36 for TREMFYA 100 mg/mL syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. TREMFYA (guselkumab) is a monoclonal antibody used to treat moderate to severe plaque psoriasis and other...
- The Defense Logistics Agency awarded a $60,405.91 delivery order to AmerisourceBergen Drug Corp for TREMFYA 100 mg/ml syringes on August 7, 2025, with completion scheduled for August 8, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TREMFYA (guselkumab) is a biologic immunosuppressant used to treat plaque psoriasis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $9,132.68 to AmerisourceBergen Drug Corp for TREMFYA 100 mg/ml syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. TREMFYA is a prescription biologic medication used to treat moderate to severe plaque psoriasis and...
- The Defense Logistics Agency awarded a delivery order valued at $54,902.36 to AmerisourceBergen Drug Corp for the supply of TREMFYA 100 mg/ml syringes on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. TREMFYA (guselkumab) is a biologic medication used to treat moderate to severe plaque...
- The Defense Logistics Agency awarded a $59,710.11 delivery order to AmerisourceBergen Drug Corp for TREMFYA 100 mg/ml syringes, with performance to be completed by July 31, 2025. This is a firm fixed price, non-competitive delivery order executed on July 30, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a $29,944.86 delivery order to AmerisourceBergen Drug Corp for TREMFYA 100 mg/mL pharmaceutical product on August 7, 2025, with completion scheduled for August 8, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and specifies performance at the contractor's Conshohocken, Pennsylvania facility. TREMFYA is a biologic medication used primarily for treating moderate-to-severe plaque psoriasis and is being procured to...
- The Defense Logistics Agency awarded a delivery order valued at $7,269.70 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of TREMFYA 200 mg/2 ml syringes. This competitive, non-set-aside contract has a firm fixed price structure with an ultimate completion date of September 4, 2025, and will be performed at the awardee's facility in Conshohocken, Pennsylvania. TREMFYA is a prescription biologic medication used in the treatment of plaque psoriasis and psoriatic arthritis, and...
- The Defense Logistics Agency awarded a delivery order valued at approximately $24,948 to AmerisourceBergen Drug Corp for TREMFYA 100 mg/mL syringes. This firm fixed price contract was competitively awarded without set-aside provisions and is set to be completed by August 12, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TREMFYA is a prescription biologic medication used in the treatment of psoriasis and psoriatic arthritis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for TREMFYA 100 mg/ml syringes valued at $7,683.48 on August 13, 2025, with completion scheduled for August 14, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside award to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. TREMFYA is a specialty immunosuppressant injection used to treat psoriasis and psoriatic arthritis, reflecting the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,522.26 to AmerisourceBergen Drug Corp for TREMFYA 100 mg/ml pharmaceutical product on September 19, 2025, with a completion date of September 22, 2025. This firm fixed price contract, with no set-aside designation, was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TREMFYA is a biologic medication used to treat certain immune-mediated inflammatory...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFF3MDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $69,595.64 to AmerisourceBergen Drug Corp for TREMFYA 100 MG/ML syringes on October 20, 2025, with completion expected by October 21, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. TREMFYA (guselkumab) is a biologic immunosuppressant medication used primarily to treat moderate-to-severe plaque psoriasis, reflecting the Defense Health System's need for specialized pharmaceutical products to support military personnel and veteran healthcare requirements. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor within the federal medical supply chain, leveraging this comprehensive IDC to supply an extensive portfolio of brand-name and generic medications, biologics, vaccines, and medical supplies to support military healthcare programs globally. The company's competitively awarded federal contracts demonstrate its capability to meet stringent federal procurement requirements across multiple therapeutic domains and delivery scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $69.6k | 10/20/25 |